Macmillan's Response To NICE's Interim Decision Not To Recommend Colorectal Cancer Drug

Main Category: Colorectal Cancer
Also Included In: Cancer / Oncology
Article Date: 26 Aug 2010 - 4:00 PDT

email to a friend   printer friendly   opinions  

Responding to the interim decision by NICE not to recommend bevacizumab (Avastin) as a treatment for metastic colorectal cancer, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:

'We think this is devastating news for cancer patients with metastic colorectal cancer, especially as this drug could have a significant impact on peoples' quality of life. Although a few extra weeks or months might not sound much to some people it can mean an awful lot to a family affected by cancer.

'Again this reiterates just how important it is that the government's cancer drug fund comes into place sooner rather than later. On behalf of people living with cancer, Macmillan will hold the government to their £200 million commitment in order to ensure people with rarer cancers have fair access to clinically effective drugs.'

Source:
Macmillan Cancer Support

• Additional
• References
• Citations